| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEF1 |
| Uniprot No | Q9HAY2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-307aa |
| 氨基酸序列 | MLQTPESRGLPVPQAEGEKDGGHDGETRAPTASQERPKEELGAGREEGAAEPALTRKGARALAAKALARRRAYRRLNRTVAELVQFLLVKDKKKSPITRSEMVKYVIGDLKILFPDIIARAAEHLRYVFGFELKQFDRKHHTYILINKLKPLEEEEEEDLGGDGPRLGLLMMILGLIYMRGNSAREAQVWEMLRRLGVQPSKYHFLFGYPKRLIMEDFVQQRYLSYRRVPHTNPPEYEFSWGPRSNLEISKMEVLGFVAKLHKKEPQHWPVQYREALADEADRARAKARAEASMRARASARAGIHLW |
| 预测分子量 | 35,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAGEF1重组蛋白的3篇模拟参考文献及其摘要概括(注：文献为示例性虚构，实际研究中请核实真实文献)：
1. **文献名称**：*"Cloning and functional characterization of recombinant MAGEF1 in cancer cell proliferation"*
**作者**：Zhang Y, et al.
**摘要**：本研究成功在大肠杆菌中表达了重组MAGEF1蛋白，并证实其在多种肿瘤细胞系中异常高表达。实验表明，MAGEF1通过调控细胞周期蛋白加速肿瘤细胞增殖，提示其作为潜在治疗靶点。
2. **文献名称**：*"Structural analysis of MAGEF1 recombinant protein reveals its ATPase-dependent molecular mechanism"*
**作者**：Smith JL, et al.
**摘要**：通过X射线晶体学解析了重组MAGEF1蛋白的三维结构，发现其N端含有保守的MAGE结构域，且依赖ATP水解参与蛋白相互作用。该研究为理解MAGEF1在肿瘤发生中的功能提供了结构基础。
3. **文献名称**：*"MAGEF1 recombinant protein promotes melanoma metastasis via modulating immune checkpoint expression"*
**作者**：Lee H, et al.
**摘要**：利用重组MAGEF1蛋白进行体外实验，发现其通过上调PD-L1表达抑制T细胞活性，进而促进黑色素瘤转移。研究揭示了MAGEF1在肿瘤免疫逃逸中的新机制。
4. **文献名称**：*"Development of a MAGEF1-specific monoclonal antibody using recombinant protein immunization"*
**作者**：Brown K, et al.
**摘要**：通过重组MAGEF1蛋白免疫小鼠，成功筛选出高特异性单克隆抗体，并验证其在临床组织样本中的诊断应用潜力，为MAGEF1相关癌症的检测提供了新工具。
(注：以上文献及作者为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索确认。)
**Background of MAGE-F1 Recombinant Protein**
MAGE-F1 (Melanoma-associated antigen F1), also known as NDNL2 or MAGED2. is a member of the MAGE (Melanoma Antigen Gene) protein family, which shares a conserved MAGE homology domain (MHD). These proteins are often classified as cancer-testis antigens due to their restricted expression in normal tissues (primarily testes and placenta) but frequent overexpression in various cancers. MAGE-F1 is implicated in cellular processes such as apoptosis regulation, cell cycle control, and ubiquitination pathways, though its precise molecular mechanisms remain under investigation.
The recombinant MAGE-F1 protein is engineered through molecular cloning, typically expressed in *E. coli* or mammalian systems, followed by purification to ensure high specificity and activity. Its recombinant form enables functional studies, including protein-protein interaction assays, structural analysis, and antibody production. Research highlights its potential role in tumorigenesis, with studies linking MAGE-F1 overexpression to cancer progression, immune evasion, and chemoresistance in malignancies like melanoma, lung cancer, and hepatocellular carcinoma.
Additionally, MAGE-F1 has garnered interest in immunotherapy due to its cancer-specific expression, making it a candidate for targeted therapies, including vaccines or CAR-T cells. However, challenges such as its intracellular localization and homology with other MAGE proteins necessitate further exploration. Overall, recombinant MAGE-F1 serves as a critical tool for deciphering its biological roles and advancing diagnostic or therapeutic strategies in oncology.
×
